142 related articles for article (PubMed ID: 37978322)
21. Comparison of fludarabine-melphalan and fludarabine-treosulfan as conditioning prior to allogeneic hematopoietic cell transplantation-a registry study on behalf of the EBMT Acute Leukemia Working Party.
Duque-Afonso J; Finke J; Labopin M; Craddock C; Protheroe R; Kottaridis P; Tholouli E; Byrne JL; Orchard K; Salmenniemi U; Hilgendorf I; Hunter H; Nicholson E; Bloor A; Snowden JA; Verbeek M; Clark A; Savani BN; Spyridonidis A; Nagler A; Mohty M
Bone Marrow Transplant; 2022 Aug; 57(8):1269-1276. PubMed ID: 35568756
[TBL] [Abstract][Full Text] [Related]
22. Allogeneic hematopoietic cell transplantation in patients with myelodysplastic syndrome using treosulfan based compared to other reduced-intensity or myeloablative conditioning regimens. A report of the chronic malignancies working party of the EBMT.
Shimoni A; Robin M; Iacobelli S; Beelen D; Mufti GJ; Ciceri F; Bethge W; Volin L; Blaise D; Ganser A; Luft T; Chevallier P; Schwerdtfeger R; Koster L; de Witte T; Kröger N; Nagler A; Yakoub-Agha I
Br J Haematol; 2021 Nov; 195(3):417-428. PubMed ID: 34514596
[TBL] [Abstract][Full Text] [Related]
23. Predicting non-relapse mortality following allogeneic hematopoietic cell transplantation during first remission of acute myeloid leukemia.
Yanada M; Konuma T; Mizuno S; Saburi M; Shinohara A; Tanaka M; Marumo A; Sawa M; Uchida N; Ozawa Y; Onizuka M; Yoshioka S; Nakamae H; Kondo T; Kimura T; Kanda J; Fukuda T; Atsuta Y; Nakasone H; Yano S
Bone Marrow Transplant; 2021 Feb; 56(2):387-394. PubMed ID: 32796950
[TBL] [Abstract][Full Text] [Related]
24. Allogeneic haemopoietic transplantation for acute myeloid leukaemia in second complete remission: a registry report by the Acute Leukaemia Working Party of the EBMT.
Gilleece MH; Labopin M; Savani BN; Yakoub-Agha I; Socié G; Gedde-Dahl T; Blaise D; Byrne JL; Craddock C; Cornelissen JJ; Arcese W; Forcade E; Crawley C; Polge E; Mohty M; Nagler A
Leukemia; 2020 Jan; 34(1):87-99. PubMed ID: 31363160
[TBL] [Abstract][Full Text] [Related]
25. Effect of age on outcome of reduced-intensity hematopoietic cell transplantation for older patients with acute myeloid leukemia in first complete remission or with myelodysplastic syndrome.
McClune BL; Weisdorf DJ; Pedersen TL; Tunes da Silva G; Tallman MS; Sierra J; Dipersio J; Keating A; Gale RP; George B; Gupta V; Hahn T; Isola L; Jagasia M; Lazarus H; Marks D; Maziarz R; Waller EK; Bredeson C; Giralt S
J Clin Oncol; 2010 Apr; 28(11):1878-87. PubMed ID: 20212255
[TBL] [Abstract][Full Text] [Related]
26. Impact of risk scores in outcome of patients with myeloid neoplasms after allogeneic stem cell transplant.
Fernández-Caballero M; Jiménez Lorenzo MJ; Morgades de la Fe M; Ferrà Coll C; Vives Polo S; Abril Sabater L; Navarro Ferrando JT; Ribera Santasusana JM
Med Clin (Barc); 2022 May; 158(10):451-457. PubMed ID: 34404519
[TBL] [Abstract][Full Text] [Related]
27. Role of HCT-comorbidity index, age and disease status at transplantation in predicting survival and non-relapse mortality in patients with myelodysplasia and leukemia undergoing reduced-intensity-conditioning hemopoeitic progenitor cell transplantation.
Bokhari SW; Watson L; Nagra S; Cook M; Byrne JL; Craddock C; Russell NH
Bone Marrow Transplant; 2012 Apr; 47(4):528-34. PubMed ID: 21743502
[TBL] [Abstract][Full Text] [Related]
28. Comparison of umbilical cord blood allogeneic stem cell transplantation vs. auto-SCT for adult acute myeloid leukemia patients in second complete remission at transplant: a retrospective study on behalf of the SFGM-TC.
Chevallier P; Labopin M; Socie G; Rubio MT; Blaise D; Vigouroux S; Huynh A; Michallet M; Bay JO; Maury S; Yakoub-Agha I; Fegueux N; Deconinck E; Contentin N; Maillard N; Bulabois CE; Francois S; Oumedaly R; Raus N; Mohty M
Eur J Haematol; 2015 May; 94(5):449-55. PubMed ID: 25238651
[TBL] [Abstract][Full Text] [Related]
29. Patient age and donor HLA matching can stratify allogeneic hematopoietic cell transplantation patients into prognostic groups.
Garcia-Horton A; Cyriac SL; Gedde-Dahl T; Floisand Y; Remberger M; Mattsson J; Michelis FV
Eur J Haematol; 2022 Dec; 109(6):672-679. PubMed ID: 36028979
[TBL] [Abstract][Full Text] [Related]
30. The impact of HLA-matching on reduced intensity conditioning regimen unrelated donor allogeneic stem cell transplantation for acute myeloid leukemia in patients above 50 years-a report from the EBMT acute leukemia working party.
Rubio MT; Savani BN; Labopin M; Polge E; Niederwieser D; Ganser A; Schwerdtfeger R; Ehninger G; Finke J; Renate A; Craddock C; Kröger N; Hallek M; Jindra P; Mohty M; Nagler A
J Hematol Oncol; 2016 Aug; 9(1):65. PubMed ID: 27488518
[TBL] [Abstract][Full Text] [Related]
31. Allogeneic Hematopoietic Cell Transplantation for Adolescent and Young Adult Patients with Acute Myeloid Leukemia.
Mizuno S; Takami A; Kawamura K; Arai Y; Kondo T; Kawata T; Uchida N; Marumo A; Fukuda T; Tanaka M; Ozawa Y; Yoshida S; Ota S; Takada S; Sawa M; Onizuka M; Kanda Y; Ichinohe T; Atsuta Y; Yanada M
Transplant Cell Ther; 2021 Apr; 27(4):314.e1-314.e10. PubMed ID: 33836873
[TBL] [Abstract][Full Text] [Related]
32. Pretransplantation Plasma ST2 Level as a Prognostic Biomarker of 1-Year Nonrelapse Mortality in Allogeneic Hematopoietic Cell Transplantation.
Gjærde LK; Ostrowski SR; Schierbeck F; Andersen NS; Friis LS; Kornblit B; Petersen SL; Schjødt I; Sengeløv H
Transplant Cell Ther; 2023 Feb; 29(2):97.e1-97.e6. PubMed ID: 36375798
[TBL] [Abstract][Full Text] [Related]
33. Long-term clinical outcomes of hematopoietic cell transplantation for intermediate-to-poor-risk acute myeloid leukemia during first remission according to available donor types.
Yoon JH; Kim HJ; Park SS; Jeon YW; Lee SE; Cho BS; Eom KS; Kim YJ; Lee S; Min CK; Cho SG; Kim DW; Lee JW; Min WS
Oncotarget; 2017 Jun; 8(25):41590-41604. PubMed ID: 28206975
[TBL] [Abstract][Full Text] [Related]
34. Allogeneic transplantation with myeloablative FluBu4 conditioning improves survival compared to reduced intensity FluBu2 conditioning for acute myeloid leukemia in remission.
Magenau JM; Braun T; Reddy P; Parkin B; Pawarode A; Mineishi S; Choi S; Levine J; Li Y; Yanik G; Kitko C; Churay T; Frame D; Riwes MM; Harris A; Bixby D; Couriel DR; Goldstein SC
Ann Hematol; 2015 Jun; 94(6):1033-41. PubMed ID: 25784222
[TBL] [Abstract][Full Text] [Related]
35. Comparable Outcomes After Alternative and Matched Sibling Donor Hematopoietic Stem Cell Transplantation and the Role of Molecular Measurable Residual Disease for Acute Myeloid Leukemia in Elderly Patients.
Cho BS; Yahng SA; Min GJ; Park S; Park SS; Shin SH; Jeon YW; Yoon JH; Lee SE; Eom KS; Kim YJ; Lee S; Min CK; Cho SG; Kim DW; Lee JW; Kim M; Kim Y; Kim HJ
Transplant Cell Ther; 2021 Sep; 27(9):774.e1-774.e12. PubMed ID: 34082159
[TBL] [Abstract][Full Text] [Related]
36. Poor outcome with nonmyeloablative conditioning regimen before cord blood transplantation for patients with high-risk acute myeloid leukemia compared with matched related or unrelated donor transplantation.
Devillier R; Harbi S; Fürst S; Crocchiolo R; El-Cheikh J; Castagna L; Etienne A; Calmels B; Lemarie C; Prebet T; Granata A; Charbonnier A; Rey J; Chabannon C; Faucher C; Vey N; Blaise D
Biol Blood Marrow Transplant; 2014 Oct; 20(10):1560-5. PubMed ID: 24933658
[TBL] [Abstract][Full Text] [Related]
37. [Second allogeneic hematopoietic stem cell transplantation with reduced-intensity conditioning and donor changes in relapsed hematological malignancies after the first allogeneic transplant].
Zhao YQ; Song YZ; Li ZH; Yang F; Xu T; Li FF; Yang DF; Wu T
Zhonghua Xue Ye Xue Za Zhi; 2023 Jun; 44(6):465-471. PubMed ID: 37550201
[No Abstract] [Full Text] [Related]
38. Allogeneic hematopoietic cell transplantation (HCT) following reduced-intensity conditioning in patients with acute leukemias.
Niederwieser D; Gentilini C; Hegenbart U; Lange T; Becker C; Wang SY; Bartsch K; Pönisch W; Raida M; Al-Ali H
Crit Rev Oncol Hematol; 2005 Nov; 56(2):275-81. PubMed ID: 16213741
[TBL] [Abstract][Full Text] [Related]
39. Analysis of Real-world Data on Postremission Therapy for Acute Myeloid Leukemia With Intermediate Risk Cytogenetics in First Complete Remission.
Vydra J; Šálek C; Schwarz J; Žák P; Novák J; Petečuková V; Pecherková P; Mayer J; Cetkovský P; Ráčil Z
Clin Lymphoma Myeloma Leuk; 2018 Feb; 18(2):106-113. PubMed ID: 29289481
[TBL] [Abstract][Full Text] [Related]
40. Sustained remissions of high-risk acute myeloid leukemia and myelodysplastic syndrome after reduced-intensity conditioning allogeneic hematopoietic transplantation: chronic graft-versus-host disease is the strongest factor improving survival.
Valcárcel D; Martino R; Caballero D; Martin J; Ferra C; Nieto JB; Sampol A; Bernal MT; Piñana JL; Vazquez L; Ribera JM; Besalduch J; Moraleda JM; Carrera D; Brunet MS; Perez-Simón JA; Sierra J
J Clin Oncol; 2008 Feb; 26(4):577-84. PubMed ID: 18086801
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
